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Abstract
Purpose The histological response to neoadjuvant chemo-
therapy is an important prognostic factor in patients with os-
teosarcoma (OS) and Ewing sarcoma (EWS). The aim of this
study was to assess baseline primary tumour FDG uptake on
PET/CT, and serum values of alkaline phosphatase (ALP) and
lactate dehydrogenase (LDH), to establish whether these fac-
tors are correlated with tumour necrosis and prognosis.
Methods Patients treated between 2009 and 2014 for localized
EWS and OS, who underwent FDG PET/CT as part of their
staging work-up, were included. The relationships between pri-
mary tumour SUVmax at baseline (SUV1), SUVmax after in-
duction chemotherapy (SUV2), metabolic response calculated
as [(SUV1 − SUV2)/SUV1)] × 100, LDH andALP and tumour
response/survival were analysed. A good response (GR) was
defined as tumour necrosis >90 % in patients with OS, and
grade II-III Picci necrosis (persitence of microscopic foci only
or no viable tumor) in patients with Ewing sarcoma.
Results The study included 77 patients, 45 with EWS and 32
with OS. A good histological response was achieved in 53 %
of EWS patients, and 41 % of OS patients. The 3-year event-
free survival (EFS) was 57 % in EWS patients and 48 % OS
patients. The median SUV1 was 5.6 (range 0 – 17) in EWS
patients and 7.9 (range 0 – 24) in OS patients (p = 0.006). In
EWS patients the GR rate was 30 % in those with a high
SUV1 (≥6) and 72 % in those with a lower SUV1 (p =
0.0004), and in OS patients the GR rate was 29 % in those
with SUV1 ≥6 and 64 % in those with a lower SUV1 (p =
0.05). In the univariate analysis the 3-year EFS was signifi-
cantly better in patients with a low ALP level (59 %) than in
those with a high ALP level (22 %, p = 0.02) and in patients
with a low LDH level (62 %) than in those with a high LDH
level (37 %, p = 0.004). In EWS patients the 3-year EFS was
37 % in those with a high SUV1 and 75 % in those with a low
SUV1 (p = 0.004), and in OS patients the 3-year EFS was
32 % in those with a high SUV1 and 66 % in those with a
low SUV1 (p = 0.1). Histology, age and gender were not as-
sociated with survival. In the multivariate analysis, SUV1 was
the only independent pretreatment prognostic factor to retain
statistical significance (p = 0.017). SUV2 was assessed in 25
EWS patients: the median SUV2 was 1.9 (range 1 – 8). The
GR rate was 20 % in patients with a high SUV2, and 67 % in
those with a low SUV2 (p = 0.02). A goodmetabolic response
(SUV reduction of ≥55 %) was associated with a 3-year EFS
of 80 % and a poor metabolic response with a 3-year EFS of
20 % (p = 0.05). In the OS patients the median SUV2 was 2.7
(range 0 – 4.5). Neither SUV2 nor the metabolic response was
associated with outcome in OS patients.
Conclusion FDG PET/CT is a useful and noninvasive tool for
identifying patients who are more likely to be resistant to
chemotherapy. If this finding is confirmed in a larger series,
SUV1, SUV2 and metabolic response could be proposed as
factors for stratifying EWS patients to identify those with
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high-grade localized bone EWS who would benefit from risk-
adapted induction chemotherapy.
Keywords Ewing sarcoma . Osteosarcoma . PET-CT .
Prognosis . Neo-adjuvant chemotherapy . SUV1
Introduction
Osteosarcoma (OS) and Ewing sarcoma (EWS) are the most
frequent primitive bone tumours, with an incidence ranging
from 0.2 to 0.3/100,000/year [1, 2]. The combination of
multiagent chemotherapy, surgery and also radiotherapy in
patients with EWS have dramatically improved the prognosis,
with disease-free survival rates at 5 years of about 65 – 70 %
[1]. Tumour necrosis induced by neoadjuvant chemotherapy
is one of the most powerful prognostic indicators of survival
in patients with localized disease [3, 4]. Tumour response to
neoadjuvant chemotherapy has important implications in sub-
sequent patient management and some clinical trials have in-
dicated that postoperative treatment should be based on histo-
logical response [5, 6]. However, pathological assessment of
tumour response is only possible after resection. Therefore, an
accurate and noninvasive predictive marker of response is
important in designing an individualized treatment strategy
in patients with localized bone sarcoma. This is particularly
relevant in patients with nonextremity EWS who are under-
going radiotherapy as definitive treatment, and therefore lack
histological response data [7, 8].
18F-FDG PET/CT is now widely used in the initial diagno-
sis, staging and detection of recurrence in many kinds of can-
cer [9–14]. The role of 18F-FDG PET/CT in predicting re-
sponse to chemotherapy in bone sarcomas [15–22] and soft-
tissue sarcomas [23–25] has been assessed in many studies
with contradictory results [19, 26]. However, histological het-
erogeneity [23, 24], limited numbers of patients included [16,
19], and especially the lack of uniform treatment [15] make
the interpretation of results difficult.
The aim of the present study was to assess the prognostic
role of 18F-FDG uptake and its correlation with histological
response to chemotherapy, in a single-institutional series of
patients with EWS and OS of bone prospectively enrolled in
a clinical trial (for EWS, EudraCT no. 2008-008361-35; for
OS, EudraCT no. 2011-001659-36).
Materials and methods
All patients treated between April 2009 and February 2014 for
localized EWS and OS enrolled in the ISG-AIEOP-EW1 and
ISG/OS2 protocols, respectively and who had undergone
FDG PET/CT as part of staging work-up were included.
EWS and OS protocol design
EWS patients enrolled in the ISG-AEIOP-EW1 protocol
(EudraCT no. 2008-008361-35) were randomized into two
arms with the same drugs delivered according to different
dose intensities. In both arms patients received induction treat-
ment followed by surgery (whenever possible) and/or radio-
therapy. The maintenance treatment was given according to
the response to the induction treatment (Fig. 1).OS patients
enrolled in the ISG/OS2 protocol (EudraCT no. 2011-001659-
36) underwent induction chemotherapy with methotrexate
12 g/m2 (cycles 1 and 3), and cisplatinum 120 mg/m2 and
doxorubicin (Adriamycin) 75 mg/m2 (cycles 2 and 4). After
surgery, patients were stratified to receive a different chemo-
therapy according to P-glycoprotein (ABCB1) expression and
histological response. A total body FDG PET/CT scan was
performed in all patients at the time of diagnosis.
FDG PET/CT imaging
Standardized uptake values (SUVmax) at baseline (SUV1)
were calculated for primary tumours and recorded (Fig. 1).
SUV1 is reported as median and groups were compared using
Student’s t test. The threshold for SUV1 was identified as the
median plus 1 SD of the baseline. SUV2 was defined as the
SUVmax of the primary tumour after induction chemotherapy
and is reported as the median (Fig. 1). The threshold for SUV2
was identified as the median plus 1 SD.
Response assessment
Metabolic response
Metabolic responses (percentage reduction in glucose uptake) to
primary chemotherapy were calculated according as:[(SUV1 −
SUV2)/SUV1)] × 100. Metabolic responses are reported as me-
dians and the threshold was set as the median plus 1 SD.
Each patient received 3.7 MBq/kg of 18F-FDG intrave-
nously and the PET/CT scan was performed 60 – 90 min
after tracer administration. 18F-FDG was produced in our
radiopharmacy using a standard technique. PET/CT scans
were carried out on a dedicated PET/CT tomograph
(Discovery LS; GE Medical System, Waukesha, WI;
Fig. 2). PET emission images were collected for 2 min for
each bed position from the vertex of the skull to the thighs
with inclusion of the upper extremities, and the CT scan was
used for nonuniform attenuation correction. CT acquisition
parameters were: 120 kV, 80 mA, 0.8 s tube rotation,
3.7 mm slice thickness. To optimize FDG uptake in normal
and neoplastic tissues, patients were asked to fast for at least
6 h and were encouraged to void to minimize activity in the
bladder before the PET/CT scan. None of the patients had a
history of diabetes.
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Histological/radiological response
Tumour response to chemotherapy was evaluated in all pa-
tients. In EWS patients, a histological good response (GR)
was defined as grade II/III Picci necrosis in those undergoing
surgery [3]. In patients undergoing radiation therapy only, as a
local treatment, complete disappearance of the soft tissue
component on MRI was considered a GR. In OS patients,
the tumour map was analysed histologically in accordance
with a previously reported method [27]. The response was
considered a GR if tumour necrosis was ≥90 %.
Laboratory analysis
In all patients a chemistry panel and complete blood
count tests were performed before the start of chemo-
therapy including alkaline phosphatase (ALP) and lac-
tate dehydrogenase (LDH). The normal ranges for ALP
at our institution are defined according to gender and
age: in males aged <12, 13 – 17 and >17 years the up-
per limits of the normal ranges are 300, 390 and 129
U/l, and in females are 300, 187 and 104 U/l,
respectively.
Fig. 2 18F-FDG PET/CT images
in a 37-year-old woman with a
left iliac Ewing sarcoma before (a
SUV1 10) and after (b SUV2 3.2)
chemotherapy
Fig. 1 Chemotherapy treatment
schedule for the treatment of
patients with localized bone
tumours
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Statistical analysis
Event-free survival (EFS) was calculated from the first day of
chemotherapy to recurrence (local or distant) or
chemotherapy-related death, to the appearance of secondary
tumours or to the last follow-up examination. Survival curves
were calculated by the Kaplan-Meier method and compared
using the log-rank test. In univariate analysis for EFS the
following parameters were evaluated: histology (OS vs.
EWS), pathological response to chemotherapy (good vs.
poor), serum ALP levels (high vs. normal) and LDH levels
(high vs. normal), age (adult vs. paediatric) and gender (fe-
male vs. male). The relationship between primary tumour
SUV1 and SUV2 and tumour histological response/survival
was also analysed.
Results
The study included 77 patients, 45 with EWS and 32 with OS.
and of these 77 patients, 52 (67 %) were male and 25 (33 %)
female (Table 1). The mean age of the patients at presentation
was of 17 years (range 3 – 39 years). The primary tumour was
located in the extremities in 58 (75%) of the patients (femur in
26, tibia in 17, fibula in 8, humerus in 5), and in the axial
skeleton in 19 patients (pelvis in 14, sacrum in 2, spine in 2,
and scapula in 1). The 3-year EFS was 35 % in patients with
high SUV1, and 72 % in patients with low SUV1 (p = 0.001)
overall (Fig. 3a). The median SUV1 was 6.7 (range 0 – 24)
overall. The median baseline LDH was 224 U/l (range 61 –
841 U/l), and the median ALP was 109 U/l (10 – 1,006 U/l).
The median chemotherapy-induced tumour necrosis was
93 % (range 40 – 100 %). Histological or radiological GR
was achieved in 37 of the 77 patients (48 %) overall. The best
SUV1 threshold for predicting response was 6 (Fig. 4). With
the cut-off set at 6 (SUV1), the GR rate was 29 % in patients
with a high SUV1 (≥6) and 69 % in patients with a low SUV1
(<6; p = 0.0004) overall.
Treatment, SUV1, histological response and histological
outcome
Ewing sarcoma
Of the 45 EWS patients 28 (62 %) received surgery and 17
(38%) received external beam radiotherapy as local treatment.
In the latter group, the decision to perform external beam
radiotherapy rather than surgery was taken on a case-by-case
basis by the orthopaedic surgeons, and was primarily based on
age and site. In EWS patients the median SUV1 was 5.6
(range 0 – 17). Histological or radiological GR was achieved
in 24/(53 %) of the 45 patients, with a complete histological
response in 11 patients (24 %). The GR rate was 30 % in
patients with a high SUV1 and 72 % in those with a low
SUV1 (p = 0.004; Fig. 5). In EWS patients the 3-year EFS
was 37 % in those with a high SUV1 and 75 % in those with
a low SUV1 (p = 0.004; Fig. 3b).
Osteosarcoma
All OS patients underwent surgical treatment. Their median
SUV1 was 7.85 (range 0 – 24). Histological or radiological
GR was achieved in 13 (41 %) of the 32 patients, with a
complete histological response in 3 patients (9 %). The GR
rate was 20 % in patients with a high SUV1 and 64 % in those
with a low SUV1 (p = 0.05; Fig. 5). In OS patients the 3-year
EFS was 32 % in those with a high SUV1 and 66 % in those
with a low SUV1 (p = 0.1; Fig. 3c).
Table 1 Clinical characteristics of the patients in the ISG-AIEOP-EW-
1 and ISG/OS2 studies
ISG-AIEOP-EW-1 ISG/OS2
No. of patients 45 32
Age (years)
Median 16 17
Range 3 – 37 6 – 39
Sex, n (%)
Male 33 (73) 19 (59)
Female 12 (27) 13 (41)
Site, n (%)
Extremities 27 (60) 31 (97)
Pelvis 14 (31) 0 (0)
Spine 4 (9) 0 (0)
Scapula 0 (0) 1 (3)
Alkaline phosphatase, n (%)
Normal 44 (98) 24 (75)
High 1 (2) 8 (25)
Lactate dehydrogenase, n (%)
Normal 33 (73) 24 (75)
High 12 (27) 8 (25)
Local therapy, n (%)
Surgery 28 (62) 32 (100)
External beam radiotherapy 17 (38) 0
SUV1
Median 5.6 7.8
Range 0 – 17 0 – 24
SUV2
Median 1.9 2.7
Range 0 – 8 0 – 4.5
Response to induction chemotherapy, n (%)
Good 24 (53) 13 (41)
Poor 21 (47) 19 (59)
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Univariate and multivariate analysis for event-free
survival
The results of the univariate analysis for EFS are shown in
Table 2. The 3-year EFS was significantly better in patients
with a low SUV1 (72 %) than in those with a high SUV1
(36 %, p = 0.002), in those with a low ALP level (59 %) than
in those with a high ALP level (22 %, p = 0.02), and in those
with a low LDH level (62 %) than in those with a high LDH
level (37 %, p = 0.004). However, histology, age and gender
were not associated with survival. Combining SUV1 and
LDH, four prognostic groups were identified, with worse sur-
vival in patients with a high SUV1, independent of LDH level
(Table 2).
In the multivariate analysis, SUV1 was the only indepen-
dent pretreatment prognostic factor to retain statistical signif-
icance (p = 0.017; Table 3).
Metabolic response: SUV2
The results discussed in this section relate exclusively to the
25 patients with localized EWS and 12 patients with localized
OS who underwent a PET scan for reassessment after induc-
tion chemotherapy.
Ewing sarcoma
The median SUV2 was 1.9 (range 1 – 8), with a median met-
abolic response of 59 % (range 7 – 99 %). The GR rate was
20 % in patients with a high SUV2 (≥3) and 67 % in those
with a low SUV2 (<3; p = 0.02). The 3-year EFS was 80 % in
patients with a good metabolic response (reduction in SUVof
≥55 %) and 20 % in those with a poor metabolic response
(reduction in SUVof <55 %; p = 0.05; Fig. 6).
Osteosarcoma
The median SUV2 was 2.7 (range 0 – 4.5) with a median
metabolic response of 48 % (range 4 – 99 %). The GR rate
was 50% in patients with a high SUV2 (≥3) and 75% in those
with a low SUV2 (<3; p = 0.4). The 3-year EFS was 20 % in
patients with a good metabolic response (reduction in SUVof
Fig. 3 Event-free survival (EFS)
at 3 years in relation to SUV1
(low <6, high ≥6) in (a) localized
bone sarcoma (OS+EWS), (b)
Ewing sarcoma (EWS) and (c)
osteosarcoma (OS)
Fig. 4 Event-free survival (EFS) at 3 years in relation to SUV1 (<6, 6 –
9, >9) in localized bone sarcoma
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≥55 %) and 100 % in those with a poor metabolic response
(reduction in SUVof <55 %; p not assessable).
Discussion
A histological response to neoadjuvant chemotherapy is one
of the strongest prognostic factors in patients with OS [27–29]
and EWS [3, 30]. Histological response has significant limi-
tations, including the ability to assess it only after 10 to
15 weeks of initial chemotherapy. The current study repre-
sents the largest series of patients with bone sarcomas in
which the prognostic value of pretreatment SUV1 was
assessed (Table 4). This study showed an association between
SUV1 and histological/radiological response in patients with
OS and in those with EWS. SUV1 was also predictive of
outcome in terms of EFS in patients with EWS, with a trend
in patients with OS. This is in contrast with Hawkins et al.
paper, founding no differences in EFS at 4-year (63 % vs.
73 %, p 0.4), in a series of 34 localized OS, with a median
age of 15 [31].
To our knowledge, this is the first report of an association
between SUV1 and EFS in patients with EWS. Multivariate
analysis confirmed SUV1 as and independent prognostic fac-
tor, and SUV1 should be take into consideration together with
other well-known prognostic factors such as patient age, and
tumour site and size [3, 29]. The strength of this study was the
homogeneity of treatment, including the duration of neoadju-
vant chemotherapy, the surgical team and pathological assess-
ment, all important determinants of EFS that could be con-
founding factors in assessing the predictive value of FDG
PET. The concordance between a good histological response
(>90% tumour necrosis in OS patients and Picci II/III necrosis
in EWS patients) and SUV1 (<6) in this study was very ro-
bust, confirming the findings in smaller series [15, 16, 32, 33],
and is in contrast with the findings of a study performed in
Table 2 Univariate analysis of clinical and pathological variables for
event-free survival (EFS) in patients with localized bone sarcoma
Variable Number of
patients
3-year EFS (95 % CI) p value
Overall 77 57 % (41 − 73 %)
Histology
Ewing sarcoma 45 57 (38 – 77) 0.5
Osteosarcoma 32 48 (25 – 71)
Age (years)
≤18 51 53 (33 – 74) 0.9
>18 26 52 (29 – 76)
Gender
Female 37 64 (41 – 86) 0.3
Male 40 46 (26 – 66)
SUV1
<6 31 72 (51 – 92) 0.002
≥6 46 36 (14 – 57)
LDH (baseline)
Low 55 62 (44 – 80) 0.004
High 22 37 (13 – 61)
ALP (baseline)
Low 68 59 (43 – 75) 0.02
High 9 22 (0 – 57)
SUV1/LDH (baseline)
<6 LDH low 29 78 (59 – 98) 0.00007
LDH high 6 56 (7 – 100)
≥6 LDH low 36 36 (6 – 67)
LDH high 16 34 (10 – 50)
Fig. 5 Relationship between
primary tumour SUVmax at
baseline (SUV1) and tumour
histological response
Table 3 Multivariate analysis of clinical and pathological variables for
event-free survival in patients with localized bone sarcoma
Variable Relative risk 95 % CI p value
Histology
Osteosarcoma 1 0.623
Ewing sarcoma 1.25 0.50 – 3.11
SUV1
Low 1 0.017
High 3.25 1.24 – 8.52
LDH
Low 1 0.07
High 2.18 0.93 – 5.14
ALP
Low 1 0.20
High 2.06 0.68 – 6.23
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America [31]. Differences in patient characteristics (age),
treatment and histological examination assessment could ex-
plain these conflicting results.
FDG PET may have several potential clinical uses. First,
treating physicians may be able to identify patients who are
more likely to have a less favourable histological response to
neoadjuvant chemotherapy. Such patients would be candi-
dates for more aggressive front-line chemotherapy.
Nonrandomized clinical trials have suggested that augmenta-
tion of chemotherapy in response to a poor histological re-
sponse can improve outcome [34, 35]. However, this obser-
vation has been refuted in other studies [36, 37], including the
randomized European and American Osteosarcoma Study
Group trial (EURAMOS-1), in which the hypothesis that a
response-adapted therapy would provide a survival benefit
was not confirmed [38].
It is possible that SUV1-adapted chemotherapy would
be more useful than histological response-adapted chemo-
therapy, because of the ability to identify chemotherapy-
resistant patients from the beginning of therapy.
Furthermore, combining SUV1 level with one or more
already validated prognostic factors such as patients age
or LDH level could eventually identify a ‘prognostic
score’, similar to those used in other malignancies such
as breast cancer. SUV2 seems exclusively useful in EWS
patients. In our study SUV2 was able to predict histolog-
ical response, as shown in a paediatric series [32], and
might be used for example by surgeons to plan a local
Fig. 6 Event-free survival (EFS)
at 3 years according to metabolic
response after induction
chemotherapy in patients with
localized Ewing sarcoma
Table 4 Studies on the use of FDG PET in localised bone sarcoma including outcome correlation and SUV thresholds






End-point SUV threshold Survival (%) p value
[7] 2005 18.7 36a Ewing sarcoma 7.9 4-year PFS <6 62 0.47
≥6 52
[31] 2009 15 40b Osteosarcoma 6.8 4-year PFS >6 73 0.41
≤6 63
[15] 2002 13.3 18 Osteosarcoma 8.2 ND
15 Ewing sarcoma 5.3 ND
[22] 2009 14 70 Osteosarcoma 8 ND
[20] 2013 21 26 Osteosarcoma 9.2 ND
[16] 2002 14 26 Osteosarcoma 12.6 3-year EFS 12.6 90
28
<0.005
[25] 1996 19 4 Osteosarcoma 5.8 ND
16 1 Ewing sarcoma 5.8
[19] 2006 17.5 10 Osteosarcoma 9.1 ND
[32] 2016 12.6 50 Ewing sarcoma 5 ND
Palmerini et al. this study 17 32 Osteosarcoma 7.8 3-year EFS <6 66 0.1
≥6 32
16 45 Ewing sarcoma 5.6 3-year EFS <6 75 0.004
≥6 37
EFS Event-free survival, PFS Progression-free survival, ND not done
a 12 metastatic
b 6 metastatic
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treatment approach. Furthermore, a good metabolic re-
sponse was associated with best survival in EWS patients
(80 % 3-year EFS in patients with a reduction in SUV2 of
≥55 %, in contrast to 20 % in patients with a poor meta-
bolic response). In OS patients metabolic response did not
appear to be a valid prognostic tool, in contrast by previ-
ously reported findings in children and young adults [31].
The major limitation of this subanalysis was the small
sample size.
In conclusion, this is an important study on the role of PET
in the management of localized bone sarcomas. The study
demonstrated that an SUV1 <6 before neoadjuvant chemo-
therapy was an independent prognostic factor for EFS. The
study confirmed that FDG PET imaging can complement his-
tological response. Only in EWS patients was a good meta-
bolic response associated with the best survival, and a treat-
ment algorithm based on FDG PET/CT data could be pro-
posed in patients with localized EWS (Fig. 7). Additional
research should prospectively address the impact on survival
of treatment modification in patients who are at greater risk of
disease recurrence.
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